Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

British journal of clinical pharmacology - 1 Mar 2018

Polasek Thomas M, Tucker Geoffrey T, Sorich Michael J, Wiese Michael D, Mohan Titus, Rostami-Hodjegan Amin, Korprasertthaworn Porntipa, Perera Vidya, Rowland Andrew

Abstract excerpt

AIM: The aim of the present study was to predict olanzapine (OLZ) exposure in individual patients using physiologically based pharmacokinetic modelling and simulation (PBPK M&S). METHODS: A 'bottom-up' PBPK model for OLZ was constructed in Simcyp® (V14.1) and validated against pharmacokinetic studies and data from therapeutic drug monitoring (TDM). The physiological, demographic and genetic attributes of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Cytochrome P-450 CYP2C8

Share to Drug Monitoring

Share to Models, Biological

Share to Olanzapine

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 29194718
DOI: 10.1111/bcp.13480
PMCID: PMC5809347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.PMID 29194718Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

Effect of Genetic Variants, Gender, and Co-treatment on Olanzapine Plasma Concentration in Chinese patients with schizophreniaSemantic proximity Read ↗

Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy.Semantic proximity Read ↗

A Digital Twin of Glimepiride for Personalized and Stratified Diabetes TreatmentSemantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

Pharmacogenetics of Olanzapine MetabolismSemantic proximity Read ↗

Living systematic review and meta-analysis of plasma-concentrations of antipsychotic drugs in carriers and non-carriers of variant CYP450 genotypes: Living systematic review protocolSemantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization.Semantic proximity Read ↗

Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.